Because of the importance of the IGF1R pathway in cancers, various inhibitors, including monoclonal antibodies and small molecules targeting IGF1R or IGF-1, have been developed, most of which are undergoing clinical trials.45 To the best of our knowledge, this is the first report to establish the signaling axis of MTAP-IGF1R. Here, MTAP is linked to cancer.